Top

11-10-2017 | Colorectal cancer | Article

Comparative Safety of Targeted Therapies for Metastatic Colorectal Cancer between Elderly and Younger Patients: a Study Using the International Pharmacovigilance Database

Journal: Targeted Oncology

Authors: Amandine Gouverneur, Pauline Claraz, Marine Rousset, Mickaël Arnaud, Annie Fourrier-Réglat, Antoine Pariente, Thomas Aparicio, Ghada Miremont-Salamé, Pernelle Noize

Publisher: Springer International Publishing

Abstract

Background

Metastatic colorectal cancer (mCRC) is increasingly treated using targeted therapies. Post-marketing safety of these agents is understudied, especially in the elderly.

Objective

This study aimed to compare, according to age, the adverse drug reactions (ADRs) of targeted therapies used for mCRC in real life.

Patients and Methods

An extraction of VigiBase, which contains World Health Organization individual case safety reports (ICSRs), was performed. All ADR reports with aflibercept, bevacizumab, cetuximab, panitumumab, or regorafenib used in CRC were considered. For all drugs, chi-square tests were used to compare frequencies of serious ADRs between patients aged ≥75 and <75 years. For selected ADRs and each drug, the drug-ADR association compared to other anticancer drugs was estimated through the proportional reporting ratio (PRR) in both age groups.

Results

There were 21,565 ICSRs included, among which 74% were serious and 11% were fatal. Median age was 64 years (Inter Quartile Range = 56–71) and 15% of patients were aged ≥75; 57% were male. Serious ICSRs accounted for 47,292 ADRs. Neutropenia was not more reported in elderly for all drugs while diarrhea was more reported in elderly for panitumumab. Cardiac disorders were more reported in elderly patients, in particular heart failure, especially for bevacizumab, cetuximab, and regorafenib, as were respiratory, thoracic, and mediastinal disorders. Most of PRR were not different between the two groups, except encephalopathies, which were significantly associated with bevacizumab in the elderly only.

Conclusions

ADRs related to targeted therapies used for mCRC treatment were different across age groups; yet, not systematically more reported or worse in elderly patients. Selected elderly patients could, therefore, be treated with these targeted therapies.

Howlader N, Noone A, Krapcho M, Miller D, Bishop K, Altekruse S, et al. SEER Cancer Statistics Review, 1975-2013, National Cancer Institute. Bethesda, MD. Based on November 2015 SEER data submission, posted to the SEER web site, April 2016. http://seer.cancer.gov/csr/1975_2013/sections.html Accessed 15 June 2017.

Del Rio M, Mollevi C, Vezzio-Vie N, et al. Specific extracellular matrix remodeling signature of colon hepatic metastases. PLoS One. 2013;8:e74599.CrossRefPubMedPubMedCentral

Van Cutsem E, Cervantes A, Adam R, et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol. 2016;27:1386–422.CrossRefPubMed

Papamichael D, Audisio R, Glimelius B, et al. Treatment of colorectal cancer in older patients: International Society of Geriatric Oncology (SIOG) consensus recommendations 2013. Ann Oncol. 2015;26:463–76.CrossRefPubMed

Talarico L, Chen G, Pazdur R. Enrollment of elderly patients in clinical trials for cancer drug registration: a 7-year experience by the US Food and Drug Administration. J Clin Oncol. 2004;22:4626–31.CrossRefPubMed

Aparicio T, Pamoukdjian F, Quero L, et al. Colorectal cancer care in elderly patients: Unsolved issues. Dig Liver Dis. 2016;48:1112–8.CrossRefPubMed

Gouverneur A, Salvo F, Berdaï D, et al. Inclusion of elderly or frail patients in randomized controlled trials of targeted therapies for the treatment of metastatic colorectal cancer: A systematic review. J Geriatr Oncol. 2017; https://doi.org/10.1016/j.jgo.2017.08.001.

Kozloff M, Berlin J, Flynn P, et al. Clinical outcomes in elderly patients with metastatic colorectal cancer receiving bevacizumab and chemotherapy: results from the BRiTE observational cohort study. Oncology. 2010;78:329–39.CrossRefPubMed

Rouyer M, Fourrier-Réglat A, Smith D, et al. Effectiveness and safety of first-line bevacizumab plus FOLFIRI in elderly patients with metastatic colorectal cancer: Results of the ETNA observational cohort. J Geriatr Oncol. 2016;7:187–94.CrossRefPubMed

10.

Jehn C, Böning L, Kröning H, et al. Cetuximab-based therapy in elderly comorbid patients with metastatic colorectal cancer. Br J Cancer. 2012;106:274–8.CrossRefPubMedPubMedCentral

11.

Fourrier-Réglat A, Smith D, Rouyer M, et al. Survival outcomes of bevacizumab in first-line metastatic colorectal cancer in a real-life setting: results of the ETNA cohort. Target Oncol. 2014;9:311–9.CrossRefPubMed

12.

Tahover E, Hubert A, Temper M, et al. An observational cohort study of bevacizumab and chemotherapy in metastatic colorectal cancer patients: safety and efficacy with analysis by age group. Target Oncol. 2015;10:55–63.CrossRefPubMed

13.

Lindquist M. VigiBase, the WHO Global ICSR Database System: Basic Facts. Drug Inf J. 2008;42:409–19.CrossRef

14.

Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis, and management. Lancet. 2000;356:1255–9.CrossRefPubMed

15.

Evans SJ, Waller PC, Davis S. Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiol Drug Saf. 2001;10:483–6.CrossRefPubMed

16.

Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335–42.CrossRefPubMed

17.

Van Cutsem E, Lenz H-J, Köhne C-H, et al. Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer. J Clin Oncol. 2015;33:692–700.CrossRefPubMed

18.

Kwakman JJM, Punt CJA. Oral drugs in the treatment of metastatic colorectal cancer. Expert Opin Pharmacother. 2016;17:1351–61.CrossRefPubMed

19.

Bouché O, Beretta GD, Alfonso PG, et al. The role of anti-epidermal growth factor receptor monoclonal antibody monotherapy in the treatment of metastatic colorectal cancer. Cancer Treat Rev. 2010;36(Suppl 1):S1–10.CrossRefPubMed

20.

Hurwitz H, Tebbutt N, Kabbinavar F, et al. Efficacy and safety of bevacizumab in metastatic colorectal cancer: pooled analysis from seven randomized controlled trials. Oncologist. 2013;18:1004–12.CrossRefPubMedPubMedCentral

21.

Van Cutsem E, Köhne C-H, Hitre E, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med. 2009;360:1408–17.CrossRefPubMed

22.

Asmis T, Powell E, Karapetis C, et al. Comorbidity, age and overall survival in cetuximab-treated patients with advanced colorectal cancer (ACRC)--results from NCIC CTG CO.17: a phase III trial of cetuximab versus best supportive care. Ann Oncol. 2011;22:118–26.CrossRefPubMed

23.

Jackson NA, Barrueco J, Soufi-Mahjoubi R, et al. Comparing safety and efficacy of first-line irinotecan/fluoropyrimidine combinations in elderly versus nonelderly patients with metastatic colorectal cancer: Findings from the bolus, infusional, or capecitabine with camptostar-celecoxib study. Cancer. 2009;115:2617–29.CrossRefPubMed

24.

Price TJ, Zannino D, Wilson K, et al. Bevacizumab is equally effective and no more toxic in elderly patients with advanced colorectal cancer: A subgroup analysis from the AGITG MAX trial: An international randomised controlled trial of capecitabine, bevacizumab and mitomycin C. Ann Oncol. 2012;23:1531–6.CrossRefPubMed

25.

Curigliano G, Mayer EL, Burstein HJ, et al. Cardiac Toxicity From Systemic Cancer Therapy: A Comprehensive Review. Prog Cardiovasc Dis. 2010;53:94–104.CrossRefPubMed

26.

des Guetz G, Uzzan B, Chouahnia K, et al. Cardiovascular toxicity of anti-angiogenic drugs. Target Oncol. 2011;6:197–202.CrossRefPubMed

27.

Hershman DL, Wright JD, Lim E, et al. Contraindicated use of bevacizumab and toxicity in elderly patients with cancer. J Clin Oncol. 2013;31:3592–9.CrossRefPubMedPubMedCentral

28.

Sorrentino MF, Kim J, Foderaro AE, et al. 5-fluorouracil induced cardiotoxicity: review of the literature. Cardiol J. 2012;19:453–8.CrossRefPubMed

29.

Tsai H, Marshall J, Weiss S, et al. Bevacizumab use and risk of cardiovascular adverse events among elderly patients with colorectal cancer receiving chemotherapy: a population-based study. Ann Oncol. 2013;24:1574–9.CrossRefPubMedPubMedCentral

30.

Hurwitz HI, Saltz LB, Van Cutsem E, et al. Venous thromboembolic events with chemotherapy plus bevacizumab: A pooled analysis of patients in randomized phase II and III studies. J Clin Oncol. 2011;29:1757–64.CrossRefPubMed

31.

Cunningham D, Lang I, Marcuello E, et al. Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial. Lancet Oncol. 2013;14:1077–85.CrossRefPubMed

32.

Jonker DJ, O’Callaghan CJ, Karapetis CS, et al. Cetuximab for the treatment of colorectal cancer. N Engl J Med. 2007;357:2040–8.CrossRefPubMed

33.

Kogawa T, Doi A, Shimokawa M, et al. Early skin toxicity predicts better outcomes, and early tumor shrinkage predicts better response after cetuximab treatment in advanced colorectal cancer. Target Oncol. 2015;10:125–33.CrossRefPubMed

34.

Scope A, Agero ALC, Dusza SW, et al. Randomized double-blind trial of prophylactic oral minocycline and topical tazarotene for cetuximab-associated acne-like eruption. J Clin Oncol. 2007;25:5390–6.CrossRefPubMed

35.

Alatawi YM, Hansen RA. Empirical estimation of under-reporting in the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS). Expert Opin Drug Saf. 2017;16:761–7.

36.

González-Rubio F, Calderón-Larrañaga A, Poblador-Plou B, et al. Underreporting of recognized adverse drug reactions by primary care physicians: an exploratory study. Pharmacoepidemiol Drug Saf. 2011;20:1287–94.CrossRefPubMed